Title: TOPICAL COMPOSITION CONTAINING PENCICLOVIR

Abstract

An oil-in-water or an aqueous topical pharmaceutical formulation for the treatment of virus infections of the skin or mucosa, comprising at least 30% propylene glycol, at least 0.75% penciclovir and 0.5 to 1% Cetomacrogol 1000.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FI</td>
<td>Finland</td>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>FR</td>
<td>France</td>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GA</td>
<td>Gabon</td>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GN</td>
<td>Guinea</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>GR</td>
<td>Greece</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>HU</td>
<td>Hungary</td>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IE</td>
<td>Ireland</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>IT</td>
<td>Italy</td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>JP</td>
<td>Japan</td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KP</td>
<td>Democratic People’s Republic of Korea</td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d’Ivoire</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>SU</td>
<td>Soviet Union</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>CS</td>
<td>Czechoslovakia</td>
<td>LU</td>
<td>Luxembourg</td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>MC</td>
<td>Monaco</td>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td>ES</td>
<td>Spain</td>
<td>MG</td>
<td>Madagascar</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This invention relates to a topical pharmaceutical formulation suitable for use in the treatment of virus infections of the skin and mucosa.

EP-A-141927 (Beecham Group p.l.c.) discloses the compound 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine, known as BRL 39123 or penciclovir, its salts and esters thereof and its use in the treatment of herpesvirus infections. Topical administration is disclosed as a suitable route. Hereinafter, references to penciclovir include salts and esters thereof.

It is important with a topical formulation of an antiherpesvirus drug that the quantity of drug released from the formulation is sufficient to exert a significant antiviral effect and that the drug rapidly reaches its site of action within the skin.

Rapid penetration is important, since in most cases, major virus induced epidermal pathology occurs within the first 24 hours post infection. Once the infection is established and the stratum corneum has been eroded, the rapid ingress of host resistant factors could make chemotherapy of questionable value.

WO 91/11187 (Beecham Group p.l.c.) discloses an oil-in-water topical pharmaceutical formulation or an aqueous formulation for the treatment of virus infections of the skin or mucosa, comprising at least 30% of propylene glycol and solubilised penciclovir.

A new antiviral topical formulation has now been discovered, having improved properties as compared with conventional formulations.

Accordingly, the present invention provides an oil-in-water topical pharmaceutical formulation or an aqueous formulation for the treatment of virus infections of the skin or mucosa, comprising at least 30% of propylene glycol, at least 0.75% penciclovir and 0.5 to 1% Cetomacrogol 1000.

Such a topical formulation may contain up to 10% w/w penciclovir and
from 30% to 60% w/w of propylene glycol and from 15% w/w water (up to 50% when there is an oil phase).

In a preferred aspect the formulation comprises from 0.75 or 1% to 10% w/w penciclovir, from 30% to 50% w/w of propylene glycol, from 20% w/w water (up to 40%, when there is an oil phase). Examples of suitable formulations comprise from 2% to 5% w/w penciclovir, from 35% to 45% w/w of propylene glycol, from 25% to 40% w/w water together with an oil phase. A preferred formulation, however, comprises 0.75% or 1% to 5% penciclovir. The formulation should preferably contain about 40% w/w of propylene glycol.

The amount of penciclovir present in the formulation should be at least sufficient to maintain an antivirally effective concentration at the site of infection between applications without showing signs of toxicity. The optimum concentration of penciclovir will depend on its solubility in the vehicle. Penciclovir may be included in the formulation at a level exceeding its solubility in order to provide a reservoir and to maintain the antiviral agent at a saturated concentration within the vehicle. One suitable amount in the above preferred formulation is up to 10% w/w, such as 2-8%, for example 5%. A preferred amount is less than 5%, such as 0.5 - 2%, for example 1%.

The water used in the formulation is preferably purified water, purified
that is by distillation by means of ion exchange or other appropriate
method, such as reverse osmosis.

The oil phase of the emulsions of this invention may be constituted from
known ingredients in a known manner. While the phase may comprise
merely an emulsifier (otherwise known as an emulgent), it is desirably
comprised of a mixture of at least one emulsifier with one or more
excipients including oils, fats and/or waxes, together with optional film
formers and stabilisers as well as thickening and bodying agents.
Preferably, as explained in more detail below, an additional hydrophilic
emulsifier is included together with a lipophilic emulsifier which acts as a
stabiliser. It is also preferred to include both an oil and a fat. Together,
the emulsifier(s) make up the so-called emulsifying wax, and the wax
together with the oil and/or fat make up the so called emulsifying
ointment base which forms the oil dispersed phase of the emulsions.

Oil-in-water topical formulations may be formulated in a number of ways, all of which depend primarily on the alignment of the emulgent or emulsifying agent and emulsion stabiliser at the oil/water interface, with the non-polar or lipophilic groups soluble in the oil phase and the polar or hydrophilic groups in the aqueous or continuous phase. Thus the more polar hydrophilic emulgents result in oil-in-water emulsions. This principle has been systemised in the idea of a 'hydrophilic-lipophilic balance' (H.L.B.) Griffen, W. C. J. Soc. Cosmet. Chem., 1954, 5, 249 and the various emulgents have been allocated H.L.B. numbers from which their behaviour with constituents of the aqueous and oil phases (to which they are applied theoretical required H.L.B. figures) may be predicted.

The emulsion stabiliser for use in the formulation of the present invention is Cetomacrogol 1000 (Polyethylene Glycol 1000 Monocetyl Ether) present in a proportion of 0.5 to 1% by weight, such as 0.7 to 1.0%, preferably 0.9% to 1.0%, the optimum concentration being 0.94%.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties. Thus the cream should preferably be non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Lipophilic substances with relatively high melting points, such as beeswax, partial glycerides of capric and caprylic acids, or silicone oil, white soft paraffin and/or liquid paraffin or other mineral or vegetable oils are suitable. Straight or branched chain, mono- or dibasic alkyl esters such as di-isopropyladipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a mixed ester of 2-ethyl hexanoic acid with a blend of cetyl or stearyl alcohols known as Crodamol CAP may also be used.

As well as creams, the aqueous/oil-in-water formulation may be a lotion, skin paint, gel, spray, aerosol, liniment or gel stick, which are formulated as known in the art, for example as described in standard text books of pharmaceutics and cosmetics, such as Harry's Cosmetology published by Leonard Hill Books, the British Pharmacopoeia, USP twenty-first revision (USP XXI) (1984), distributed by Mack Publishing Company.
The product may or may not be sterile, with adequate preservative capacity for single or multi-dose purposes.

In this description, the following terms are employed:

**Aerosol** - Pharmaceutical aerosols are products that are packaged under pressure and contain therapeutically active ingredients that are released upon activation of an appropriate valve system. The term 'aerosol' has been used to refer to the fine mist of spray that is emitted from a pressurized container containing an active ingredient and a propellant. However, the term has been broadly applied to include all self-contained pressurized products, some of which deliver foams or semisolid fluids. Accordingly, unless indicated otherwise, a reference herein to an aerosol formulation of the present invention should be understood to include pharmaceutical compositions for topical use comprising a pharmaceutically acceptable carrier which includes a propellant, said compositions being adapted for use in a pressurized container that dispenses the composition as a spray, foam or semisolid liquid.

An aerosol generally comprises a container, a propellant, a concentrate containing the active ingredient, a valve (which may be a metered valve), and an actuator. The nature of these components determines characteristics such as delivery rate, foam density, and fluid viscosity.

Aerosols may be two-phase (gas and liquid) or three-phase (gas, liquid, and solid or liquid formulations. A two-phase formulation consists of a solution of active ingredients in liquidified propellant and the vaporized propellant. The solvent may be the propellant or a mixture of the propellant and co-solvents such as alcohol and polyethylene glycols which are often used to enhance the solubility of the active ingredients. Three-phase formulations consist of a suspension or emulsion of the active ingredient(s) in addition to the vaporized propellants. A suspension consists of the active ingredient(s) dispersed in the propellant system with the aid of suitable excipients such as wetting agents and/or solid carriers such as talc or colloidal silicas. A foam formulation is generally an emulsion containing one or more active ingredients, surfactants, aqueous or nonaqueous liquids, and the propellants. If the propellant is in the internal (discontinuous) phase (i.e., of the oil-in-water type), a stable foam
is discharged, and if the propellant is in the external (continuous) phase (i.e., of the water-in-oil type), a spray or a quick-breaking foam is discharged. [See The United States Pharmacopeia, XXI ('USP') at 1334].

Gels - Gels are semisolid systems consisting either of suspensions made up of small inorganic particles or of large organic molecules interpenetrated by a liquid. Where the gel consists of a network of small discrete particles, the gel is classified as a two-phase system. In a two-phase gel, if the particle size of the dispersed phase is relatively large, the gel is sometimes referred to as a magma. Both gels and magmas may be thixotropic, forming semisolids on standing and becoming liquid on agitation.

Single-phase gels consist of organic macromolecules uniformly distributed throughout a liquid so that no apparent boundaries exist between the dispersed macromolecules and the liquid. Single-phase gels may be made from synthetic macromolecules (e.g. Carbomer)* or from natural gums (e.g. Tragacanth). The latter preparations are also called mucilages.

Although single-phase gels are commonly aqueous, alcohols and oils may also be used as the continuous phase. For example, mineral oil can be combined with a polyethylene resin to form a gel which may be used as an oleaginous ointment base [see USP, supra at 1336].

Lotion - Preferred lotions include fluid or thixotropic emulsions intended for external application to the body. These lotions are emulsions of the oil-in-water type stabilized by a surface-active agent. They may separate or stratify on long standing, and should be well shaken before each use. Adequate preservation against microbial contamination is required [see USP, supra at 1337].


*Excipients that are italicised in this discussion are classified as pharmacopoeial preparations (USP or BP).
**Liniment** - Liniments are solutions or mixtures of various substances in oil, alcoholic solutions of soap, or emulsions, as in the present invention. They are intended for external application and are usually applied with friction and rubbing of skin, the oil or soap base providing for ease of application and massage.

**Spray** - As used in this description, spray formulations are aqueous solutions of various drugs which are applied topically from a container having a spray means (e.g., an atomizer or nebulizer).

The present invention further provides a method for the preparation of a topical pharmaceutical formulation, as hereinbefore defined, which comprises mixing the combination of penciclovir, propylene glycol, Cetomacrogol 1000 and water, optionally with oil phase.

The manner of formulating an emulsion will of course vary according to the amount and nature of the constituents, but nevertheless follows known techniques in emulsion technology (see The Pharmaceutical Codex, London, The Pharmaceutical Press, 1979). In a preferred method penciclovir may be included in the oil phase prior to emulsification with the aqueous portion. Alternatively the penciclovir may be initially incorporated wholly in the aqueous portion where it may form a solution alone, or mixed solution/suspension, and then emulsified with the ointment base, or a part of the aqueous portion may be formulated as an emulsion, and the balance of the water, propylene glycol and penciclovir added to and dispersed into the emulsion. In using these procedures, it is preferable to heat the aqueous portion and the ointment base to about 40 to 80°C, preferably 50 to 70°C, prior to emulsification which may be achieved by vigorous agitation using for example a standard laboratory mixer. Finer dispersions of the oil phase may be obtained by homogenising or milling in a colloidal mill.

A topical formulation of the present invention may be used in the treatment or prevention of viral infections caused by herpesviruses such as herpes simplex types 1 and 2 and varicella-zoster virus.

The formulation should be applied to the affected area 2 to 6 times daily,
preferably 2 or 3 times.

The following examples illustrate the invention.

5

CREAMS CONTAINING PROPYLENE GLYCOL

% w/w

Example 1

10

Aqueous phase
Cetomacrogol 1000  0.90
Propylene glycol  40.00
Purified Water  26.74

Oil phase
Cetostearyl alcohol  7.41
Liquid paraffin  5.70
BRL 39123 (penciclovir)  5.00
White soft paraffin  14.25

Example 2

Aqueous Phase
Cetomacrogol 1000  0.90
Propylene Glycol  40.00
Purified Water  25.30

Oil Phase
Cetostearyl Alcohol  7.80
Liquid Paraffin  6.00
White Soft Paraffin  15.00
BRL 39123 (penciclovir)  5.00
### Example 3

**Aqueous Phase**
- Cetomacrogol 1000: 0.85
- Propylene Glycol: 40.00
- Purified Water: 26.79

**Oil Phase**
- Cetostearyl Alcohol: 7.41
- Liquid Paraffin: 5.70
- White Soft Paraffin: 14.25
- BRL 39123 (penciclovir): 5.00

### Example 4

**Aqueous Phase**
- Cetomacrogol 1000: 0.94
- Propylene Glycol: 41.79
- Purified Water: 27.94

**Oil Phase**
- Cetostearyl Alcohol: 7.74
- Liquid Paraffin: 5.96
- BRL 39123 (penciclovir): 0.75
- White Soft Paraffin: 14.88
Example 5

<table>
<thead>
<tr>
<th>Aqueous Phase</th>
<th>% w/w</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cetomacrogol 1000</td>
<td>0.94</td>
</tr>
<tr>
<td>Propylene Glycol</td>
<td>41.68</td>
</tr>
<tr>
<td>Purified Water</td>
<td>27.87</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oil Phase</th>
<th>% w/w</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cetostearyl Alcohol</td>
<td>7.72</td>
</tr>
<tr>
<td>Liquid Paraffin</td>
<td>5.94</td>
</tr>
<tr>
<td>BRL 39123 (penciclovir)</td>
<td>1.00</td>
</tr>
<tr>
<td>White Soft Paraffin</td>
<td>14.85</td>
</tr>
</tbody>
</table>

Example 6

<table>
<thead>
<tr>
<th>Aqueous Phase</th>
<th>% w/w</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cetomacrogol 1000</td>
<td>0.93</td>
</tr>
<tr>
<td>Propylene Glycol</td>
<td>41.26</td>
</tr>
<tr>
<td>Purified Water</td>
<td>27.58</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oil Phase</th>
<th>% w/w</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cetostearyl Alcohol</td>
<td>7.64</td>
</tr>
<tr>
<td>Liquid Paraffin</td>
<td>5.88</td>
</tr>
<tr>
<td>BRL 39123 (penciclovir)</td>
<td>2.00</td>
</tr>
<tr>
<td>White Soft Paraffin</td>
<td>14.71</td>
</tr>
</tbody>
</table>
Claims

1. An oil-in-water or an aqueous topical pharmaceutical formulation for the treatment of virus infections of the skin or mucosa, comprising at least 30% propylene glycol, at least 0.75% penciclovir and 0.5 to 1% Cetomacrogol 1000.

2. A pharmaceutical formulation according to claim 1 containing from up to 10% penciclovir, 30 to 60% propylene glycol and at least 15% water.

3. A pharmaceutical formulation according to claim 2, comprising from 30 to 50% propylene glycol and at least 20% water.

4. A pharmaceutical formulation according to claim 3 comprising 0.75 or 1 to 5% penciclovir, 35 to 45% propylene glycol and 25 to 40% water together with an oil phase.

5. A pharmaceutical formulation according to any one of claims 1 to 4, comprising 1% penciclovir.

6. A pharmaceutical formulation according to any one of claims 1 to 5 comprising 0.9 to 1.0% Cetomacrogol 1000.

7. A pharmaceutical formulation according to claim 1 substantially as described herein with reference to the examples.

8. A method for the preparation of a pharmaceutical formulation according to claim 1, which method comprises admixing the combination of penciclovir, propylene glycol, Cetomacrogol 1000 and water, optionally with an oil phase.

9. A pharmaceutical formulation according to claim 1 for use as an active therapeutic substance.

10. A pharmaceutical formulation according to claim 1 for use in the treatment of viral infections.
11. Use of a pharmaceutical formulation according to claim 1 in the manufacture of a medicament for use in the treatment of viral infections.

12. A method of treatment of viral infections in mammals, which comprises the administration of an effective amount of a pharmaceutical formulation according to claim 1.
**INTERNATIONAL SEARCH REPORT**

**I. CLASSIFICATION OF SUBJECT MATTER**

According to International Patent Classification (IPC) or to both National Classification and IPC

| Int.Cl.5 | A 61 K 31/52 | A 61 K 47/00 | A 61 K 47/10 |

**II. FIELDS SEARCHED**

<table>
<thead>
<tr>
<th>Classification System</th>
<th>Classification Symbols</th>
</tr>
</thead>
<tbody>
<tr>
<td>Int.Cl.5</td>
<td>A 61 K</td>
</tr>
</tbody>
</table>

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched.

**III. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of Document, with indication where appropriate, of the relevant passages</th>
<th>Relevant to Claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>EP,A,0416739 (BEECHAM) 13 March 1991, see the whole document</td>
<td>1-12</td>
</tr>
<tr>
<td>P,A</td>
<td>WO,A,9111187 (BEECHAM) 8 August 1991, see the whole document (cited in the application)</td>
<td>1-12</td>
</tr>
</tbody>
</table>

* Special categories of cited documents: *

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document published on or after the international filing date
- "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another document of particular relevance (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

**IV. CERTIFICATION**

Date of the Actual Completion of the International Search: 10-09-1992

Date of Mailing of this International Search Report: 30.09.92

International Searching Authority: EUROPEAN PATENT OFFICE

[Signature]

Dagmar FRANK
This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 23/09/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>JP-A- 3066618</td>
<td>22-03-91</td>
</tr>
<tr>
<td>WO-A- 9111187</td>
<td>08-08-91</td>
<td>AU-A- 7155891</td>
<td>21-08-91</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN-A- 1053547</td>
<td>07-08-91</td>
</tr>
</tbody>
</table>

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82